ZA962369B - Pharmaceutical composition and method - Google Patents

Pharmaceutical composition and method

Info

Publication number
ZA962369B
ZA962369B ZA962369A ZA962369A ZA962369B ZA 962369 B ZA962369 B ZA 962369B ZA 962369 A ZA962369 A ZA 962369A ZA 962369 A ZA962369 A ZA 962369A ZA 962369 B ZA962369 B ZA 962369B
Authority
ZA
South Africa
Prior art keywords
pct
pharmaceutical composition
sec
date
pub
Prior art date
Application number
ZA962369A
Other languages
English (en)
Inventor
Barry Anthony Murrer
Nigel Anthony Powell
Original Assignee
Johnson Matthey Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10771896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA962369(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Johnson Matthey Plc filed Critical Johnson Matthey Plc
Publication of ZA962369B publication Critical patent/ZA962369B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
    • C01F17/00—Compounds of rare earth metals
    • C01F17/20—Compounds containing only rare earth metals as the metal element
    • C01F17/247—Carbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
    • C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Geology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ZA962369A 1995-03-25 1996-03-25 Pharmaceutical composition and method ZA962369B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9506126.3A GB9506126D0 (en) 1995-03-25 1995-03-25 Pharmaceutical composition and method

Publications (1)

Publication Number Publication Date
ZA962369B true ZA962369B (en) 1996-11-18

Family

ID=10771896

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA962369A ZA962369B (en) 1995-03-25 1996-03-25 Pharmaceutical composition and method

Country Status (27)

Country Link
US (1) US5968976A (cs)
EP (1) EP0817639B1 (cs)
JP (1) JP3224544B2 (cs)
KR (1) KR100329340B1 (cs)
CN (1) CN1102393C (cs)
AT (1) ATE209923T1 (cs)
AU (1) AU702073B2 (cs)
BR (1) BR9607926A (cs)
CA (1) CA2216437C (cs)
CZ (1) CZ293494B6 (cs)
DE (4) DE122007000022I2 (cs)
DK (1) DK0817639T3 (cs)
EA (1) EA000270B1 (cs)
EE (1) EE04096B1 (cs)
ES (1) ES2170223T3 (cs)
GB (1) GB9506126D0 (cs)
HU (1) HU224198B1 (cs)
MX (1) MX9707334A (cs)
NO (1) NO313488B1 (cs)
NZ (1) NZ303260A (cs)
PL (1) PL184315B1 (cs)
PT (1) PT817639E (cs)
SK (1) SK282607B6 (cs)
TR (1) TR199701030T1 (cs)
TW (1) TW436288B (cs)
WO (1) WO1996030029A1 (cs)
ZA (1) ZA962369B (cs)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720061D0 (en) * 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
KR100956013B1 (ko) * 2001-04-23 2010-05-06 샤이어 인터내쇼날 라이센싱 비.브이. 희토류 화합물을 포함하는 신장 결석 질환 치료용 약제학적 조성물
WO2003094933A2 (en) * 2002-05-08 2003-11-20 Shire Holding Ag Use of lanthanum for the treatment of hypercalcemia and bone metastasis
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
EP1647524A3 (en) * 2002-08-14 2006-09-13 Altair Nanomaterials Inc. Rare earth metal compounds, methods of making, and methods of using the same
CN100526219C (zh) * 2002-08-14 2009-08-12 爱尔达纳米公司 稀土金属化合物、其制造方法及其使用方法
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
EP1660104B1 (en) * 2003-08-26 2010-03-10 Shire Holdings AG Pharmaceutical formulation comprising lanthanum compounds
KR20070054191A (ko) * 2004-07-27 2007-05-28 샤이어 파마세우티컬, 인크. 란탄 하이드록시 카보네이트를 이용한 고인산증 치료 방법
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
JP2008516971A (ja) * 2004-10-15 2008-05-22 アルテアーナノ，インコーポレーテッド 錠剤による負荷が軽減されるリン酸塩結合剤
ITME20040015A1 (it) * 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
GB0502787D0 (en) * 2005-02-10 2005-03-16 Ineos Silicas Ltd Pharmaceuticlly active compounds, their manufacture, compositions containing them and their use
EP1698233A1 (en) * 2005-03-01 2006-09-06 Bayer HealthCare AG Reduction of digestibility of phosphorus in animal nutrition
AU2006279343A1 (en) * 2005-08-17 2007-02-22 Altairnano, Inc. Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
JP2009504781A (ja) * 2005-08-17 2009-02-05 アルテアナノ インコーポレイテッド 家畜における高リン血症：治療のための組成物、及び治療方法
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
CN100398112C (zh) * 2006-03-24 2008-07-02 辽宁诺康生物制药有限责任公司 一种治疗血磷酸盐过多症的药物及其制备方法
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
EP1852695B1 (en) * 2006-05-05 2011-10-26 Shire International Licensing B.V. Assay for lanthanum hydroxy carbonate
CN101077338B (zh) * 2006-05-24 2012-06-20 天津大学 纳米碳酸镧口腔崩解片及制备方法
GB0714670D0 (en) * 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
WO2009118760A2 (en) * 2008-03-26 2009-10-01 Matrix Laboratories Limited Lanthanum composition
JP5643227B2 (ja) * 2009-01-21 2014-12-17 マイラン インコーポレイテッドＭｙｌａｎ Ｉｎｃ． 炭酸ランタンの崩壊製剤
WO2010106557A2 (en) * 2009-03-20 2010-09-23 Panacea Biotec Limited Stable pharmaceutical formulations comprising anhydrous lanthanum carbonate and process for preparation thereof
ES2407993T3 (es) * 2009-05-15 2013-06-17 Natco Pharma Limited Procedimiento para la preparación de carbonato de lantano dihidrato
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
ES2871021T3 (es) 2010-05-12 2021-10-28 Spectrum Pharmaceuticals Inc Hidróxido de carbonato de lantano, oxicarbonato de lantano y procedimientos de fabricación y uso
EP2441436A1 (de) * 2010-10-13 2012-04-18 Fresenius Medical Care Deutschland GmbH Phosphatbinderformulierung zur einfachen Einnahme
US8697132B2 (en) 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
US8263119B2 (en) 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
WO2012098562A2 (en) 2011-01-19 2012-07-26 Panacea Biotec Limited Liquid oral compositions of lanthanum salts
CN102432055B (zh) * 2011-09-23 2013-10-16 北京大学 用于治疗高磷血症的碳酸镧纳米颗粒、其制备方法及用途
CN102442692B (zh) * 2011-09-23 2014-08-27 北京大学 碳酸镧水合物的制备方法
EA021712B1 (ru) * 2012-06-12 2015-08-31 Общество С Ограниченной Ответственностью "Рубикон" Противовоспалительное средство для лечения контактного дерматита
CN103251648B (zh) 2013-05-15 2015-08-05 乔敏 治疗血磷酸盐过多症及缺铁性贫血症的铁基蒙脱石药物及其制备方法
WO2016051609A1 (ja) * 2014-10-02 2016-04-07 東和薬品株式会社 粒度調整された炭酸ランタン水和物からなる医薬
CN104473963B (zh) * 2014-12-24 2017-10-10 厦门科明达科技有限公司 稀土化学药碳酸镧咀嚼片的制备方法
US10058569B2 (en) * 2015-06-24 2018-08-28 Lupin Limited Lanthanum carbonate compositions
CN105125575B (zh) * 2015-08-07 2018-06-08 康臣药业(内蒙古)有限责任公司 一种治疗高磷酸盐血症药物的制备方法
US20180326141A1 (en) 2015-11-30 2018-11-15 Toray Industries, Inc. Phosphorus adsorbent, porous fiber and phosphorous adsorption column (as amended)
CN107876000A (zh) * 2017-10-30 2018-04-06 浙江大学 一种纳米除磷剂、制备方法及应用
CN110579499A (zh) * 2018-06-08 2019-12-17 北京华睿鼎信科技有限公司 一种碳酸镧或其制剂中碱式碳酸镧杂质的检定方法
MX2021004516A (es) * 2018-10-26 2021-06-15 Sumitomo Chemical Co Metodo para produccion de hidrato de carbonato de lantano.
WO2021101461A1 (en) 2019-11-21 2021-05-27 Santa Farma İlaç Sanayi̇ A.Ş. Oral solid pharmaceutical compositions comprising lanthanum carbonate octahydrate
CN111620363A (zh) * 2020-06-13 2020-09-04 南京卡文迪许生物工程技术有限公司 一种四水合碳酸镧的制备方法及其产品
EP4180048A4 (en) 2020-07-13 2024-07-10 Applause Pharma Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING A CER COMPOUND AS ACTIVE INGREDIENT
CN114477265B (zh) * 2020-11-13 2023-11-03 南京正济医药研究有限公司 一种四水碳酸镧的制备方法
CN115849429B (zh) * 2023-01-06 2024-01-23 湖南明瑞制药股份有限公司 一种小粒径四水碳酸镧的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06705B2 (ja) * 1985-12-19 1994-01-05 旭化成工業株式会社 リン酸イオンの固定化剤

Also Published As

Publication number Publication date
EA000270B1 (ru) 1999-02-25
TR199701030T1 (xx) 1998-06-22
ATE209923T1 (de) 2001-12-15
HU224198B1 (hu) 2005-06-28
EA199700266A1 (ru) 1998-02-26
CN1184428A (zh) 1998-06-10
PT817639E (pt) 2002-05-31
NZ303260A (en) 2000-01-28
CN1102393C (zh) 2003-03-05
GB9506126D0 (en) 1995-05-10
DE69617659D1 (de) 2002-01-17
DE69617659T2 (de) 2002-10-02
KR100329340B1 (ko) 2002-06-20
NO313488B1 (no) 2002-10-14
DK0817639T3 (da) 2002-04-02
KR19980703280A (ko) 1998-10-15
AU4951496A (en) 1996-10-16
EE04096B1 (et) 2003-08-15
EP0817639A1 (en) 1998-01-14
SK128897A3 (en) 1998-10-07
SK282607B6 (sk) 2002-10-08
NO974425L (no) 1997-11-24
WO1996030029A1 (en) 1996-10-03
BR9607926A (pt) 1998-06-09
MX9707334A (es) 1998-07-31
EP0817639B1 (en) 2001-12-05
HUP9900799A2 (hu) 1999-09-28
DE122007000022I2 (de) 2009-09-17
DE69617659T4 (de) 2007-09-27
HUP9900799A3 (en) 2000-10-30
CZ301797A3 (cs) 1998-07-15
JPH11503119A (ja) 1999-03-23
TW436288B (en) 2001-05-28
PL184315B1 (pl) 2002-10-31
DE122007000022I1 (de) 2007-07-12
JP3224544B2 (ja) 2001-10-29
US5968976A (en) 1999-10-19
CZ293494B6 (cs) 2004-05-12
CA2216437A1 (en) 1996-10-03
HK1008182A1 (en) 1999-05-07
AU702073B2 (en) 1999-02-11
ES2170223T3 (es) 2002-08-01
CA2216437C (en) 2002-10-22
EE9700325A (et) 1998-06-15
NO974425D0 (no) 1997-09-24
PL322450A1 (en) 1998-02-02

Similar Documents

Publication Publication Date Title
GB9506126D0 (en) Pharmaceutical composition and method
IS4397A (is) Ný lyfjablanda til meðhöndlunar á verkjum sem inniheldur staðdeyfiefni, skautuð lípíð og tríasýlglýseról
ZA953537B (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
GB9704352D0 (en) Levobupivacaine and its use
GB9704351D0 (en) Levobupivacaine and its use
ZA947894B (en) Compounds for medicinal use
SE9402880D0 (sv) New peptide derivatives
ZA951588B (en) Antitussive composition
JO1992B1 (en) Fixed pharmaceutical compounds based on the derivatives of quinpristine and dalphopristine materials and their preparation process
BR9713826A (pt) Agente de limpeza para dentaduras e método para impedir a formação de placa em dentaduras
EP0906757A3 (en) Analgesic composition comprising moxonidine and an opioid analgesic agent
MY128686A (en) Pharmaceutical composition containing selected lanthanum carbonate hydrates
PL315530A1 (en) Derivatives of 5-nitroimidazole in the form of microgranules
NO981320L (no) Oral anvendelse av (+)-O-demetyltramadol som smertemiddel
UA17188A (uk) Гомеопатичний лікувальний засіб "кордалон-arn"